Uganda & Mapp Biopharmaceutical

Uganda: Uganda has reported cases of the Bundibugyo strain of Ebola, making it a focus for the World Health Organization's efforts to implement clinical trials for experimental treatments and vaccines.

Mapp Biopharmaceutical: Mapp Biopharmaceutical developed MBP134, one of the experimental treatments prioritized by the World Health Organization for the Bundibugyo strain of Ebola.

Uganda: Confirmed 20 cases and 2 deaths; implementing cross-border surveillance and response measures.

Mapp Biopharmaceutical: Supplying experimental MBP134 antibody for trials; potential positive impact if treatment proves effective.

Uganda: Uganda>>> has reported confirmed Ebola cases linked to the outbreak in the Democratic Republic of the Congo>>>, leading to border closures and heightened surveillance efforts, while also expressing concern over the Uganda — Bundibugyo virus being named after one of its districts.

Mapp Biopharmaceutical: Mapp Biopharmaceutical>>>'s pan-ebolavirus antibody drug, MBP134, is a potential candidate for clinical trials against the Uganda — Bundibugyo strain, with development backed by BARDA.